Feb 08th 2013 - Edison Investment Research today published a report on quickview entitled "An Array Of Opportunities". In summary, the report says:
Multiple potential catalysts in 2013 could add significant value to Array’s currently fair EV of $430m. Array’s extensive oncology pipeline will reach a key milestone in 2013 when its first candidate enters Phase III studies – Novartis will initiate a pivotal trial of its licensed MEK inhibitor (MEK162) for NRAS melanoma in April 2013. AstraZeneca is also expected to finally make a Phase III decision on its licensed MEK inhibitor (selumetinib) in H213. Array’s own drug candidates, ARRY-520 and ARRY-614, could also enter pivotal trials by the end of 2013, pending additional data from ongoing studies. New partners may be secured for Phase II assets in the fields of pain or asthma.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »